Research ExplorerPublicationsPan-keratin Immunostaining in Human Tumors: A Tissue Microar...

Pan-keratin Immunostaining in Human Tumors: A Tissue Microarray Study of 15,940 Tumors

Standard

Pan-keratin Immunostaining in Human Tumors: A Tissue Microarray Study of 15,940 Tumors. / Menz, Anne; Gorbokon, Natalia; Viehweger, Florian; Lennartz, Maximilian; Hube-Magg, Claudia; Hornsteiner, Lisa; Kluth, Martina; Völkel, Cosima; Luebke, Andreas M; Fraune, Christoph; Uhlig, Ria; Minner, Sarah; Dum, David; Höflmayer, Doris; Sauter, Guido; Simon, Ronald; Burandt, Eike; Clauditz, Till S; Lebok, Patrick; Jacobsen, Frank; Steurer, Stefan; Krech, Till; Marx, Andreas H; Bernreuther, Christian.

In: INT J SURG PATHOL, Vol. 31, No. 6, 09.2023, p. 927-938.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Menz, A, Gorbokon, N, Viehweger, F, Lennartz, M, Hube-Magg, C, Hornsteiner, L, Kluth, M, Völkel, C, Luebke, AM, Fraune, C, Uhlig, R, Minner, S, Dum, D, Höflmayer, D, Sauter, G, Simon, R, Burandt, E, Clauditz, TS, Lebok, P, Jacobsen, F, Steurer, S, Krech, T, Marx, AH & Bernreuther, C 2023, 'Pan-keratin Immunostaining in Human Tumors: A Tissue Microarray Study of 15,940 Tumors', INT J SURG PATHOL, vol. 31, no. 6, pp. 927-938. https://doi.org/10.1177/10668969221117243

APA

Menz, A., Gorbokon, N., Viehweger, F., Lennartz, M., Hube-Magg, C., Hornsteiner, L., Kluth, M., Völkel, C., Luebke, A. M., Fraune, C., Uhlig, R., Minner, S., Dum, D., Höflmayer, D., Sauter, G., Simon, R., Burandt, E., Clauditz, T. S., Lebok, P., ... Bernreuther, C. (2023). Pan-keratin Immunostaining in Human Tumors: A Tissue Microarray Study of 15,940 Tumors. INT J SURG PATHOL, 31(6), 927-938. https://doi.org/10.1177/10668969221117243

Vancouver

Menz A, Gorbokon N, Viehweger F, Lennartz M, Hube-Magg C, Hornsteiner L et al. Pan-keratin Immunostaining in Human Tumors: A Tissue Microarray Study of 15,940 Tumors. INT J SURG PATHOL. 2023 Sep;31(6):927-938. https://doi.org/10.1177/10668969221117243

Bibtex

@article{0946a159bfe44c47a2212c1bdefa7384,
title = "Pan-keratin Immunostaining in Human Tumors: A Tissue Microarray Study of 15,940 Tumors",
abstract = "To evaluate the efficiency of pan-keratin immunostaining, tissue microarrays of 13,501 tumor samples from 121 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry. In normal tissues, strong pan-keratin immunostaining was seen in epithelial cells. Staining intensity was lower in hepatocytes, islets of Langerhans, and pneumocytes but markedly reduced in the adrenal cortex. Pan-keratin was positive in ≥98% of samples in 62 (83%) of 75 epithelial tumor entities, including almost all adenocarcinomas, squamous cell and urothelial carcinomas. Only 17 of 121 tumor entities (13%) had a pan-keratin positivity rate between 25% and 98%, including tumors with mixed differentiation, endocrine/neuroendocrine tumors, renal cell carcinomas, adrenocortical tumors, and particularly poorly differentiated carcinoma subtypes. The 15 entities with pan-keratin positivity in 0.9%-25% were mostly of mesenchymal origin. Reduced/absent pan-keratin immunostaining was associated with high UICC stage (p = 0.0001), high Thoenes grade (p = 0.0183), high Fuhrman grade (p = 0.0049), advanced tumor stage (p < 0.0001) and lymph node metastasis (p = 0.0114) in clear cell renal cell carcinoma, advanced pT stage (p = 0.0007) in papillary renal cell carcinoma, and with advanced stage (p = 0.0023), high grade (p = 0.0005) as well as loss of ER and PR expression (each p < 0.0001) in invasive breast carcinoma of no special type (NST). In summary, pan-keratin can consistently be detected in the vast majority of epithelial tumors, although pan-keratin can be negative a fraction of renal cell, adrenocortical and neuroendocrine neoplasms. The data also link reduced pan-keratin immunostaining to unfavorable tumor phenotype in in epithelial neoplasms.",
author = "Anne Menz and Natalia Gorbokon and Florian Viehweger and Maximilian Lennartz and Claudia Hube-Magg and Lisa Hornsteiner and Martina Kluth and Cosima V{\"o}lkel and Luebke, {Andreas M} and Christoph Fraune and Ria Uhlig and Sarah Minner and David Dum and Doris H{\"o}flmayer and Guido Sauter and Ronald Simon and Eike Burandt and Clauditz, {Till S} and Patrick Lebok and Frank Jacobsen and Stefan Steurer and Till Krech and Marx, {Andreas H} and Christian Bernreuther",
year = "2023",
month = sep,
doi = "10.1177/10668969221117243",
language = "English",
volume = "31",
pages = "927--938",
journal = "INT J SURG PATHOL",
issn = "1066-8969",
publisher = "SAGE Publications",
number = "6",

}

RIS

TY - JOUR

T1 - Pan-keratin Immunostaining in Human Tumors: A Tissue Microarray Study of 15,940 Tumors

AU - Menz, Anne

AU - Gorbokon, Natalia

AU - Viehweger, Florian

AU - Lennartz, Maximilian

AU - Hube-Magg, Claudia

AU - Hornsteiner, Lisa

AU - Kluth, Martina

AU - Völkel, Cosima

AU - Luebke, Andreas M

AU - Fraune, Christoph

AU - Uhlig, Ria

AU - Minner, Sarah

AU - Dum, David

AU - Höflmayer, Doris

AU - Sauter, Guido

AU - Simon, Ronald

AU - Burandt, Eike

AU - Clauditz, Till S

AU - Lebok, Patrick

AU - Jacobsen, Frank

AU - Steurer, Stefan

AU - Krech, Till

AU - Marx, Andreas H

AU - Bernreuther, Christian

PY - 2023/9

Y1 - 2023/9

N2 - To evaluate the efficiency of pan-keratin immunostaining, tissue microarrays of 13,501 tumor samples from 121 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry. In normal tissues, strong pan-keratin immunostaining was seen in epithelial cells. Staining intensity was lower in hepatocytes, islets of Langerhans, and pneumocytes but markedly reduced in the adrenal cortex. Pan-keratin was positive in ≥98% of samples in 62 (83%) of 75 epithelial tumor entities, including almost all adenocarcinomas, squamous cell and urothelial carcinomas. Only 17 of 121 tumor entities (13%) had a pan-keratin positivity rate between 25% and 98%, including tumors with mixed differentiation, endocrine/neuroendocrine tumors, renal cell carcinomas, adrenocortical tumors, and particularly poorly differentiated carcinoma subtypes. The 15 entities with pan-keratin positivity in 0.9%-25% were mostly of mesenchymal origin. Reduced/absent pan-keratin immunostaining was associated with high UICC stage (p = 0.0001), high Thoenes grade (p = 0.0183), high Fuhrman grade (p = 0.0049), advanced tumor stage (p < 0.0001) and lymph node metastasis (p = 0.0114) in clear cell renal cell carcinoma, advanced pT stage (p = 0.0007) in papillary renal cell carcinoma, and with advanced stage (p = 0.0023), high grade (p = 0.0005) as well as loss of ER and PR expression (each p < 0.0001) in invasive breast carcinoma of no special type (NST). In summary, pan-keratin can consistently be detected in the vast majority of epithelial tumors, although pan-keratin can be negative a fraction of renal cell, adrenocortical and neuroendocrine neoplasms. The data also link reduced pan-keratin immunostaining to unfavorable tumor phenotype in in epithelial neoplasms.

AB - To evaluate the efficiency of pan-keratin immunostaining, tissue microarrays of 13,501 tumor samples from 121 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry. In normal tissues, strong pan-keratin immunostaining was seen in epithelial cells. Staining intensity was lower in hepatocytes, islets of Langerhans, and pneumocytes but markedly reduced in the adrenal cortex. Pan-keratin was positive in ≥98% of samples in 62 (83%) of 75 epithelial tumor entities, including almost all adenocarcinomas, squamous cell and urothelial carcinomas. Only 17 of 121 tumor entities (13%) had a pan-keratin positivity rate between 25% and 98%, including tumors with mixed differentiation, endocrine/neuroendocrine tumors, renal cell carcinomas, adrenocortical tumors, and particularly poorly differentiated carcinoma subtypes. The 15 entities with pan-keratin positivity in 0.9%-25% were mostly of mesenchymal origin. Reduced/absent pan-keratin immunostaining was associated with high UICC stage (p = 0.0001), high Thoenes grade (p = 0.0183), high Fuhrman grade (p = 0.0049), advanced tumor stage (p < 0.0001) and lymph node metastasis (p = 0.0114) in clear cell renal cell carcinoma, advanced pT stage (p = 0.0007) in papillary renal cell carcinoma, and with advanced stage (p = 0.0023), high grade (p = 0.0005) as well as loss of ER and PR expression (each p < 0.0001) in invasive breast carcinoma of no special type (NST). In summary, pan-keratin can consistently be detected in the vast majority of epithelial tumors, although pan-keratin can be negative a fraction of renal cell, adrenocortical and neuroendocrine neoplasms. The data also link reduced pan-keratin immunostaining to unfavorable tumor phenotype in in epithelial neoplasms.

U2 - 10.1177/10668969221117243

DO - 10.1177/10668969221117243

M3 - SCORING: Journal article

C2 - 35946088

VL - 31

SP - 927

EP - 938

JO - INT J SURG PATHOL

JF - INT J SURG PATHOL

SN - 1066-8969

IS - 6

ER -